Skip to content
GAIA-BTAgentic TechBio
TRY NOW (opens in new tab)
Investors
Contact
TRY NOW (opens in new tab)

GAIA-BT Series A 2026 NCD

29 SEP 2026GAIA-BT

  • Cover: GAIA-BT 2026 Corporate Profile — Patient-Guided Oncology Asset Builder, featuring GAIA-Phil and K-GEM
  • Disclaimer: forward-looking statements and permitted use of this presentation
  • Problem and need: AI has flooded hypothesis generation, shifting the bottleneck to validation decisions
  • Problem and need: five clinical failures with different failure modes and the same recurring question
  • GAIA-BT’s solution: the K-GEM ecosystem and GAIA-Phil agentic core’s patient-based closed loop
  • GAIA-BT’s solution: the Agentic TechBio operating model — 3 decision owners, 7 specialist agents, 13 partners
  • Core value drivers: two products, GAIA-Phil and Onco101
  • Core technology: 7 agents run the full hypothesis-to-validation loop
  • Core technology: Onco101, the first output of the closed loop
  • Customer validation: demand confirmed by paid PoC, R&D agreements and letters of intent
  • Market positioning: combining a validation closed loop with proprietary assets
  • Market positioning: customer segmentation — segments, demand, what GAIA-BT provides and status
  • Business model: what GAIA-BT customers receive at each contract stage
  • Sample outputs: GAIA-Verdict and GAIA-ONCO+
  • Self-reinforcing growth model: GAIA-Phil builds assets with every use
  • Self-reinforcing growth model: mid- to long-term business roadmap
  • Self-reinforcing growth model: validating repeatable paid problem-solving through hospital and biotech channels
  • Self-reinforcing growth model: converting Onco101 clinical-development evidence into a biopharma transaction
  • Self-reinforcing growth model: expanding GAIA-Corpus into governed data products and platform economics
  • Team: four core decision owners and the seven-member global advisory board
  • Company overview and organization
  • Business progress: from build phase to scale-up, 2024 to 2026
  • Investment highlight: use of proceeds and milestones for the KRW 7.8B Series A
Download PDF (5.3 MB)